Successful Long-Term Ibrutinib Treatment in a Hemodialysis Patient With Leukemic Nonnodal Mantle Cell Lymphoma

Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e176-e178. doi: 10.1016/j.clml.2020.10.007. Epub 2020 Oct 9.

Authors

Hajime Yasuda¹, Yutaka Tsukune², Tadaaki Inano², Yosuke Mori², Yasunori Ota³, Norio Komatsu²

Affiliations

¹ Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. Electronic address: [email protected].
² Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
³ Department of Pathology, Research Hospital, The Institute of Medical Science, University of Tokyo, Japan.

PMID: 33127325
DOI: 10.1016/j.clml.2020.10.007

No abstract available

Keywords: BTK inhibitor; Dialysis; Renal failure; Renal replacement therapy; Safety.

Publication types

Case Reports

MeSH terms

Adenine / analogs & derivatives*
Adenine / pharmacokinetics
Adenine / therapeutic use
Aged
Diabetic Nephropathies / physiopathology
Diabetic Nephropathies / therapy*
Humans
Lymphoma, Mantle-Cell / diagnosis
Lymphoma, Mantle-Cell / drug therapy*
Male
Piperidines / pharmacokinetics
Piperidines / therapeutic use*
Renal Dialysis
Renal Elimination / physiology*
Treatment Outcome

Substances

Piperidines
ibrutinib
Adenine